Stanford University is looking for 200 volunteers with long-term COVID-19 to test Paxlovid, in the first study of its kind in the country.

Stanford University is looking for volunteers for the nation’s first clinical trial looking at whether the antiviral drug Paxlovid can fight one of the toughest problems of COVID-19 affecting millions of people: the long-term, debilitating cluster of symptoms known as protracted COVID.

There is currently no cure, and many people turn to it
Risky and unproven methods
to try to treat themselves.

The researchers hope that the experiment will also shed light on the mystery of why it is so valued
One in five patients
It develops persistent symptoms that include brain fog, chronic fatigue, irregular blood pressure, shortness of breath and many more.

One hypothesis is that
Parts of the coronavirus that causes COVID remain hidden in the bodyIt’s causing havoc, said Upinder Singh, an infectious disease expert at Stanford University who’s running the trial with Dr. Linda Ging, co-director of the longtime COVID clinic at the medical center.

“The data suggests that this may be the case,” Singh said. Using a drug known to work on COVID, she said the hope is that it will also work on COVID for the long haul and “target that virus that’s left” in the body.

Leave a Comment